PrecisionLife to analyse OXEGENE data to improve mechanistic understanding of endometriosis and identify novel drug targets to support the development of new personalised treatments
Introduces a line-up of brands targeting key therapeutic categories for its ophthalmology segment launc
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
This acquisition will significantly strengthen Croda’s Beauty Actives portfolio and increases its exposure to targeted prestige segments
The product will be manufactured at the group's formulation manufacturing facility in Baddi, Himachal Pradesh (India)
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
The 'A+' rating reflects IOL's robust business model, diversified product portfolio
Cipla has a robust governance model focused on sustainability
PEEK brings a new quality to dental care for patients
Subscribe To Our Newsletter & Stay Updated
